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The Funding of Cancer Research
at the National Cancer Institute
Dorothy Tisevich

t may be surprising to many people
that the National Cancer Institute,
the largest research institute of the
National Institutes of Health (NIH), is
totally federally funded. Walking
through the NIH campus in Bethesda,
Maryland, one could hardly feel farther away from the bureaucracy of the
Department of Health and Human Services. The atmosphere much more
closely resembles a college campus,
with graduate students and scientists in
blue jeans and white lab coats discussing research projects over lunch in the
cafeteria, or hurrying through the corridors juggling slide carousels on the
way to a lecture. It is a unique environment, but it is not insulated from the
political pressures which dictate its
funding and, therefore, to varying degrees, dictate the conduct of scientific
research.
In order to provide a fuller appreciation of the political climate of the
National Cancer Institute, a brief historical portrait might be helpful. The
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National Cancer Institute was authorized in 1937 following the passage in
Congress of the National Cancer Institute Act. This legislation was introduced by Congressman Warren G.
Magnuson, and provided for an appropriation of $700,000 each fiscal year.
In July, 1944, the NCI became a division of the National Institutes of
Health, and the annual funding limit of $700,000 was removed. On January
22, 1971, President Nixon announced
in his State of the Union Message that
he would seek the appropriation of an
additional $100 million to launch an
intensive effort to control cancer. On
December 23, 1971, President Nixon
signed into law the National Cancer
Act of 1971, which launched the "War
on Cancer." This legislation dramatically changed the NCI: it initiated the
National Cancer Program; provided
increased authorities and responsibilities for the NCI Director; established
the President's Cancer Panel and the
23-member National Cancer Advisory

Board; and broadened the scope of
cancer control programs and information gathering/disseminating
programs.
From a political standpoint, the key
changes centered on the access of the
National Cancer Program to the President. The President's Cancer Panel is a
three member advisory group which
reports directly to the President on the
activities of the National Cancer Program. Members of the Panel meet four
times a year and attend the regular
meetings of the National Cancer Advisory Board to keep up with the most
recent developments in cancer research. The chairman of the Panel
(currently Dr. Armand Hammer of
Occidental International Corporation)
provides a direct link between the
Director, NCI and the President, and it
is this direct link to the White House
that insures that the most pressing
needs of the National Cancer Program
can be articulated quickly and easily,
bypassing the bureaucracy of DHHS

which inevitably would slow the communication process.
Funding...then and now
he passage of the Cancer Act has
had a generally positive impact on
the funding of cancer research, although in recent years there have been
significant cutbacks. Table #1 shows
the annual appropriations of the NCI
since 1967. The most dramatic increase
occurred in 1972, when Congress appropriated $378,794,000, an increase
of 64% over the 1971 appropriation of
$230,383,000. In fact, the years 1971
through 1974 saw the greatest growth
of the NCI budget since 1967: 139% for
the three year period, for an average of
46% per year. Clearly, the Nixon Administration had made cancer research
a high priority. How do the successor
administrations compare? From 19741976, the growth of the NCI appropriation was 38%, or 19% per year. During
the Carter administration, from 19761980, the NCI appropriation grew
31 %, or approximately 8% per year.
Since 1980, the increases have slowed
to an average of 3% per year (19801986). Given the inflation rate of the
past six years, that amounts to negative
growth during the Reagan administration.
Critical to the level of funding for
cancer research over the last fifteen
years is the appropriation process of
the U.S. Congress. Most of us are only
vaguely familiar with the legislative
procedures that must be followed to
obtain funds for programs of cancer
research. The starting point is the submission to Congress of the President's
Budget. This document sets forth the
administration's priorities and fiscal
program for the upcoming fiscal year
and initiates the Congressional debate
over who gets how much. Usually the
President's budget is transmitted to
Congress around the time of the State
of the Union message. House and
Senate appropriation hearings follow
in the early spring, and then the slow
process of compromise begins. If the
House and Senate fail to reach a compromise acceptable to the White
House before the beginning of the new
fiscal year, the agencies in question end
up without an appropriation. Usually
the stopgap measure in this situation is
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a continuing resolution (C.R.), which
allows the agency to obligate funds at
the prior year's appropriation level
(prorated for the period covered by the
C.R.).
However, before the President submits a budget to Congress, thus making
it a public document, there is a long
budget development or formulation
process which takes place at each agency. This is the step where NCI is able to
take advantage of one of the most
significant changes brought about by
the 1971 National Cancer Act: the ByPass Budget. Normally, the budget formulation process begins at least 18
months prior to the start of the budget
year. For example, in April of 1986 the
FYI988 budget request is being developed. At the same time, the FYl987
President's Budget is under consideration by Congress. Also at the same
time, it is the seventh month of
FY1986, and many agencies are still
reeling from the uncertainty of the final
outcome of the Gramm-Rudman-Hollings legislation. Therefore, at one
point in time, there is budget activity
on three different fiscal years.
NCI's By-Pass budget authority is
unique at NIH. This allows NCI to
submit directly to the Office of Management and Budget (OMB) a "full requirements" budget request. Generally, the funding levels requested in the
By-Pass are higher than those included
in the Department's budget, because
the Department's submission reflects
the parameters agreed upon by the
Secretary and OMBlthe President.
The By-Pass authority was established
in order to provide to the President the
unaltered, full-capacity research requirements of the National Cancer
Program. The By-Pass is available to
members of Congress upon request,
and it is through this document that
Congress is able to see how NCI has
fared through the Department's budget
formulation process. The By-Pass is
structured to inform the reader of the
recent accomplishments of the National Cancer Program and to present the
strategy for improvements in prevention, early detection, treatment, education, and information dissemination.
By comparing the narrative description
of the NCI plans in the By-Pass with the
narrative which accompanies the

DHHS budget, it is possible to see
which of the programs will receive less
than optimal funding. Often, members
of the House and Senate Appropriations committees develop questions
for the Director ofNCI, which they ask
during the appropriation hearings. Frequently the questions address the issue
of what can/cannot be done by the
NCI at the President's budget level.
These questions put the NCI Director in a rather unenviable position. As
a representative of the Executive
Branch, he is expected to support the
President's Budget. However, the
amount identified for NCI in the President's Budget is obviously less than
sufficient to fully fund the high priority
projects included in the By-Pass. If the
NCI Director states publicly that the
proposed funding in the President's
Budget is inadequate, he has just
"busted the budget" and will probably
be replaced at the administration's earliest convenience. However, it is possible to identify "additional needs" in
response to questions from committee
members which convey the information in an acceptable manner but without compromising the integrity of the
President's Budget or the National
Cancer Program.
The political agendas of various
members of the appropriation committees become evident with the annual
package of House or Senate questions
following the hearings. Several of the
members have a personal interest in the
National Cancer Program, while others
have a parochial interest. Some are
critics of some of the research programs, or the resource allocation system, or the lack of progress in the war
on cancer. Others are strong supporters of the program and ask about
research which shows great promise, or
projects which will remain unfunded,
or how NCI is coping with fewer
dollars and employees. Still others
have an interest in specific projects or
research programs which may affect
individuals, research hospitals, or universities in their districts. How well the
responses to these questions are formulated may have a direct impact on the
final appropriation for NCr. Therefore, NCI staff are keenly aware of the
importance of providing positive, honest information in response to these
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The Funding of Cancer Research continued

APPROPRIATIONS OF THE NCI
1938 - 1985

1938 THROUGH 1966 $1.331.538.220

1967

175,656,000
183,356,000

1968 .
1969 .

}

185.149,500
190,486,063
..
230,383,000

1970
1971

1972

16.20%
$2,296,568,783

..... $ 378,794,000

1973

492,205.000

1974

551,191,500

1975

691,666,000

1976

761,727,000

"TQ"

152,901,000

1977

815,000.000

83.80%

$' ',882.002.500

1978

872.388,000

1979

937,129.000

1980 ....

1,000,000,000

1981 .

989,355,000

1982

986,617,000

1983

.. .. .. .. ..

1984

987.642.000
1,081,581,000

1985

1.183.806.000

TOTAL (1938 - 1985)

$14.178.571.283

Table #1

questions.
From the perspective of the American public, there are two important
questions: what does the NCI have to
work with in the next fiscal year and
how does it use these budget resources?
Where the money gets spent is determined by several factors, how much
was appropriated; what restrictions
have been placed on how the funds are
used; where the exciting scientific developments are taking place; and the logistics involved in the competitive research award process.
Funds are allocated internally for the
NCI research programs conducted by
NCI staff (intramural) or for research
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initiated by independent investigators
outside of the federal government
(grants) or for research needs identified/required by NCI but which cannot be done by NCI staff (contracts).
In all three areas, systems are in place to
determine the relative merit of research
proposals to ensure that the best science is funded with the limited resources available. These systems consist of review of proposals or ongoing
research projects by a group of the
investigator's peers, hence the term
"peer review." Because the funding
mechanisms differ, there are differences in the peer review systems for
each. For example, grants are research

proposals prepared by independent investigators (who usually are employed
by teaching hospitals or universities)
which have "competed" against thousands of other research proposals for
limited funds but which were determined to be of sufficient priority to
merit funding. The relative ranking of
these proposals is done by the study
section, or peer review group, which
reads through the applications and
assigns scores.
There are three cycles for review of
grant proposals at NCI, so three times a
year a funding decision has to be made
by NCI staff. Before any grants can be
awarded, though, the dual review process must be completed. The second
level review of all grants is done by the
National Cancer Advisory Board
(NCAB). Following each cycle, or
round, the NCAB meets and as one
item of business approves the funding
recommendations of the study sections. Due to the volume of grant
applications, the approval is done en
bloc and only grants which have special
interest to one or more of the NCAB
members are discussed individually.
Once the NCAB has approved the
funding recommendations of the study
sections, the NCI staff may make the
awards.
The decision as to how many grants
will be awarded and which ones to fund
is the province of the NCI Executive
" Committee (director, deputy director,
division directors, and other senior
staff). With information provided by
the financial management staff and
projections from the extramural financial data staff, the Executive Committee determines how far down in the
ranking of the study section they can
afford to go. The best score a grant
proposal can achieve is 100. The worst
is 500. Therefore, the Executive Committee draws a line, usually somewhere
between 150 and 200, where everything
above the line is not awarded. In recent
years, these decisions about where to
draw the line and how many grants to
fund have become more complex.
More and more restrictions have been
placed on the way NCI spends its
money by both the Congress and
OMB. Sometimes the dollars appropriated for grants are accompanied by
language specifying that a certain num-

ber of competing grants be funded.
This can be difficult if the two do not
match. That is, there may be insufficient funds available to fully fund the
number of grants specified. This could
happen for a variety of reasons, one of
which is that predictions do not always
end up as reality. Another reason is
that the numbers game often has nothing to do with programmatic impact. In
situations such as these, NCI staff
strive to find creative solutions which
will be minimally disruptive to scientific research.

What has come out of
all this spending?
n recent years there have been a
number of advances in understanding the cancer process; these advances
are the result of research carried out in
the intramural NCI laboratories as well
as in extramural laboratories funded by
NCI through grants and contracts. The
benefits to the taxpayers of these scientific discoveries can be seen in improved cancer treatments, improved
survival rates, and better detection and
diagnosis procedures. For example, in
1973, only five percent of patients with
advanced aggressive lymph node cancer could be cured. Today the cure rate
is better than 65 percent. Another
important advance is a better understanding of how a normal cell becomes
a cancer cell. This understanding will
undoubtedly lead to still better treatments aimed at newly identified targets
for therapy. Following are some specific examples of scientific progress:
-Cancer biology research focuses on
the structure and behavior of the
cancer cell compared witl~ normal
cells. Advances have been made in
identifying changes in cancer cells
which affect resistance to chemotherapy, enable more rapid diagnosis of small collections of cancer
cells, and provide strategies for speific delivery of effective therapy. For
instance, knowledge that cancer
cells possess certain cell wall markers has led to research that attaches
cell killing (cytotoxic) substances to
monoclonal antibodies which recognize these markers. These monoclonal antibodies effectively deliver
treatment directly to the tumor.
-Molecular biology research ad-
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vances in recombinant DNA technology and molecular cloning have
enabled researchers to identify oncogenes (segments of genetic material) which are found in chromosomes of normal and malignant
cells. Differences between normal
cells and can~er cells in some tumors have been found to be as
simple as a single nucleotide change.
It has also been discovered that
chromosomes from healthy individuals contain sites which are sensitive
to breakage, and which appear to
correspond in some tumors to the
point where there has been a translocation in the DNA structure. The
discovery has great potential for
cancer screening since these sensitive sites appear to be inheritable. It
will therefore become possible to
identify individual patients at high
risk for cancer and take preventive
measures.
-A promising new cancer treatment
has been developed which uses naturally occurring cells from the patient's blood in combination with
interleukin 2. This therapy, called
adoptive immunotherapy, actually
augments the patient's own immune
system to fight cancer cells.
-Another promising clinical trial conducted by the National Surgical Adjuvant Breast Program showed that
less disfiguring surgery combined
with radiotherapy may be as effective as the modified radical mastectomy in preventing recurrence of
breast canc·er.
These are only a few examples of
advances which have been made in
recent years. All of the research which
led to these findings was closely scrutinized by the peers of the scientists
conducting the experiments or running
the research protocols.

The bottom line
he bottom line in any of these
funding decisions is the NCI commitment to basic research, where the
compelling promise of new research
advances will result in better treatment. Whether it is the independent
investigator who is up for tenure at
his/her university and needs the grant
to get past the credentials committee,
or whether it is the patient who could
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benefit from the eventual clinical treatment which could result from that
investigator's work, or whether it is the
full cadre of technical and support
personnel who depend on the grant for
their salaries, the decisions made all the
way through the budget process have
profound implications for many
people throughout the country.
In 1971, President Nixon declared
war on cancer and oversaw a great
infusion of dollars into the National
Cancer Program. Great strides have
been made since then, and the National
Cancer Institute enjoys a highly respected reputation as a premier research facility with a staff which includes some of the most well-known
and highly respected scientists in their
fields. Despite the imperfections in the
funding process, and despite the many
attempts to impose more controls over
the way NCI does its business, the
philosophy which the NCI seems to
convey to the community is that they
will do the best they can with whatever
resources available to them. This is a
challenging time for the public sector,
and the National Cancer Institute has
risen to the challenge.
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